Drugs / Pelargonium sidoides extract
last change Nov 2025 re-read 2 minutes ago

Pelargonium sidoides extract

Developed for
bronchitis · chronic bronchitis
Investigated by
Pharmbio Korea Co., Ltd.

Trials 1 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07017335 Jun → Jul 2025 Pharmbio Korea Co., Ltd. Completed No outcome recorded
Also used as a comparator or background therapy in 3 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT07161180 Background Aug → Oct 2025 overdue Pharmbio Korea Co., Ltd. Recruiting No outcome recorded
Phase 21 trial
Phase 2 NCT01420445 Comparator Sep 2011 → May 2012 chronic bronchitis Yuhan Corporation Completed No outcome recorded
Phase 31 trial
Phase 3 NCT02151734 Comparator Aug → Dec 2013 bronchitis Korea United Pharm. Inc. Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as Pelargonium sidoides extract ClinicalTrials.gov intervention name — accepted as the source's own label NCT07017335
2

NCT07161180

NCT01420445

Known as Pelargonium sidoides 11% ethanol extract “R2\_PBK\_M2301 (Pelargonium sidoides 11% ethanol extract)” NCT07017335
Known as R2_PBK_M2301 R2_PBK_M2301 (Pelargonium sidoides extract)” NCT07017335
Known as Umckamin syrup ClinicalTrials.gov intervention name — accepted as the source's own label NCT02151734
Route Oral “R2\_PBK\_M2301 is an oral tablet” NCT07017335